170
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
243
Taylor DR, Webster LR, Chun SY, Reinking J, Stegman M, Shoemaker S, Fortner B. Impact
of breakthrough pain on quality of life in patients with chronic, non-cancer pain: pati-
ent perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTCF,
Actiq). Pain Medicine 2007; 8: 281-288.
244
Twycross R, Wilcock A, Charesworth s, Dickman A. Palliative Care Formulary (2. Aufl.),
Abingdon; Radcliffe Medical Press, 2002.
245
Twycross R, Wilcock A, Thorp S. Palliative care formulary. Abingdon: Radcliffe Medical
Press, 1998.
246
Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Safety
1994; 11: 163-178.
247
Überall MA, Müller-Schwefe GHH. Sublingual fentanyl orally disintegrating tablet in dai-
ly practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Curr Med Res Opin 2011; 27(7): 1385-1394.
248
Überall MA. Mit fentanylhaltigen Fertigarzneimitteln gegen Durchbruchschmerzen
Schmerztherapie 2009; 2: 6-7.
249
Überall MA. PraxisLeitlinien DGS/DSL: Behandlung tumorbedingter Durchbruchschmer-
zen. Vortrag im Rahmen des Deutschen Schmerztags 2012.
250
Valentín Maganto V, Camps Herrero C, Carulla Torrent J, Cassinello Espinosa J, Dorta
Delgado J, Jara Sánchez C, Moreno Nogueira JA. Safety and efficacy of oral trans-
mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology
patients: the ECODIR study. Clin Transl Oncol 2005; 7(5): 205-212.
251
Vasisht N, Gever LN, Tagarro I, Finn AL. Evaluation of the single- and multiple-dose
pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin
Pharmacol 2010; 50(7): 785-791.
252
Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal
soluble film. Pain Med 2010; 11(7): 1017-1023.
253
Vasisht N, Gever LN, Tagarro I. Formulation selection and pharmacokinetic comparison
of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized,
open- label, single-dose, crossover study. Clin Drug Investig 2009; 29(10): 647-654.
254
Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evalua-
tion of short-acting opioids for treatment of breakthrough pain in patients with cancer.
Value Health 2011; 14(2): 274-281.
255
Wagemans MF, Zuurmond WW, de Lange JJ. Long-term spinal opioid therapy in termi-
nally ill cancer pain patients. Oncologist 1997; 2: 70-75.
256
Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different
routes of administration of analgesia for breakthrough pain. Palliat Med 2003; 17: 219-
221.
257
Weber M, Huber C. Documentation of severe pain, opioid doses, and opioid-related
side effects in outpatients with cancer: a retrospective study. Journal of Pain and Symp-
tom Management 1999; 17: 49-54.
Literaturverzeichnis